Clinical trial
Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer…
NCT00324376 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00324376 |
|---|---|
| Title | Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing |
| Official title | A Randomized, Cross-Over Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | Sevelamer hydrochloride |
| Enrollment | 24 |
| Start date | Mar 1, 2003 |
| Completion | May 1, 2004 |
| First posted | May 11, 2006 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: